Skip to main content

Volume 23 Supplement 1

Epacadostat, an IDO1 inhibitor, in combination with pembrolizumab: results from clinical trials in patients with advanced solid tumors

Research

Publication of this supplement was funded by Incyte Corporation (Wilmington, DE, USA) in collaboration with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The articles have undergone the journal's standard peer review process for supplements. The Supplement Editors declare that they have no competing interests.

-

  2. Immunotherapy-based combinations have emerged as standard therapies for patients with metastatic renal cell carcinoma (mRCC). Pembrolizumab, a PD-1 inhibitor, combined with epacadostat, an indoleamine 2,3-deox...

    Authors: Primo N. Lara Jr, Luis Villanueva, Carolina Ibanez, Mustafa Erman, Jae Lyun Lee, Daniel Heinrich, Oleg Nikolaevich Lipatov, Craig Gedye, Erhan Gokmen, Alejandro Acevedo, Andrey Semenov, Se Hoon Park, Rustem Airatovich Gafanov, Fatih Kose, Mark Jones, Xiaoqi Du…
    Citation: BMC Cancer 2024 23(Suppl 1):1253
    Content type: Research Published on:

  3. Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly sele...

    Authors: Irfan Cicin, Elizabeth R. Plimack, Howard Gurney, Raya Leibowitz, Boris Y. Alekseev, Francis X. Parnis, Avivit Peer, Andrea Necchi, Joaquim Bellmunt, Hiroyuki Nishiyama, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Thomas Powles and Cora N. Sternberg
    Citation: BMC Cancer 2024 23(Suppl 1):1256
    Content type: Research Published on:

  4. Indoleamine 2,3- dioxygenase 1 (IDO1) is an immunosuppressive enzyme that has been correlated with shorter disease-specific survival in patients with urothelial carcinoma (UC). IDO1 may counteract the antitumo...

    Authors: Andrea Necchi, Michiel S. Van der Heijden, Dmytro Trukhin, Avivit Peer, Howard Gurney, Boris Y. Alekseev, Francis X. Parnis, Raya Leibowitz, Maria De Santis, Petros Grivas, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Arjun V. Balar and Ronald de Wit
    Citation: BMC Cancer 2024 23(Suppl 1):1252
    Content type: Research Published on:

  5. Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing mechanisms of action may enhance clinical benefits co...

    Authors: Byoung Chul Cho, Irene Braña, Beatriz Cirauqui, Sercan Aksoy, Felix Couture, Ruey-Long Hong, Wilson H. Miller Jr, Manuel Chaves-Conde, Margarida Teixeira, Lance Leopold, Mihaela Munteanu, Joy Yang Ge, Ramona F. Swaby and Brett G. M. Hughes
    Citation: BMC Cancer 2024 23(Suppl 1):1254
    Content type: Research Published on:

  6. Pembrolizumab is a first-line therapy for certain patients with advanced/metastatic non-small cell lung cancer (NSCLC). Combining pembrolizumab with other immunotherapies may enhance tumor cell killing and cli...

    Authors: Takaaki Tokito, Oleksii Kolesnik, Jens Sørensen, Mehmet Artac, Martín Lázaro Quintela, Jong-Seok Lee, Maen Hussein, Miklos Pless, Luis Paz-Ares, Lance Leopold, Jeannie Daniel, Mihaela Munteanu, Ayman Samkari, Lu Xu and Charles Butts
    Citation: BMC Cancer 2024 23(Suppl 1):1251
    Content type: Research Published on:

  7. The combination of the checkpoint inhibitor (CPI) pembrolizumab and platinum-based chemotherapy is effective frontline therapy for advanced non-small cell lung cancer (NSCLC) lacking targetable mutations. Indo...

    Authors: Michael Boyer, Rina Hui, Damien Urban, Philip Clingan, Wu-Chou Su, Celine Devaux, Shirish Gadgeel, Marina Garassino, Lance Leopold, Jeannie Daniel, Mihaela C. Munteanu, Ayman Samkari, Yiwen Luo and Delvys Rodriguez Abreu
    Citation: BMC Cancer 2024 23(Suppl 1):1250
    Content type: Research Published on:
Submit manuscript

Follow

BMC Cancer

ISSN: 1471-2407

Contact us